Income Statement (TTM)
Genix Pharmaceuticals Corporation Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2023 01-31 |
2023 04-30 |
2023 07-31 |
2023 10-31 |
2024 01-31 |
2024 04-30 |
2024 07-31 |
2024 10-31 |
2025 01-31 |
2025 04-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 510.94 | 27.75 | 0.00 | -12.24 | -47.71 | -29.70 | 1.71 | -1.75 | -73.19 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 1,042.80 | 5.01 | 0.00 | -8.19 | -78.93 | -4.27 | 10,883.59 | -0.01 | -0.71 | |
| % of Revenue | 47.85 | 89.51 | 73.57 | 73.57 | 76.97 | 31.01 | 42.23 | 4,560.45 | 4,641.48 | 17,190.25 |
| Gross Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 |
| Change (%) | 22.91 | 221.79 | 0.00 | -23.51 | 56.61 | -41.14 | -7,952.80 | 0.03 | 0.89 | |
| % of Revenue | 52.15 | 10.49 | 26.43 | 26.43 | 23.03 | 68.99 | 57.77 | -4,460.45 | -4,541.48 | -17,090.25 |
| SG&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | -1.53 | -18.67 | 8.40 | -15.09 | -13.28 | 7.84 | -20.23 | -5.39 | -4.98 | |
| % of Revenue | 20,946.21 | 3,375.96 | 2,149.22 | 2,329.85 | 2,254.08 | 3,738.56 | 5,735.38 | 4,498.27 | 4,331.63 | 15,352.58 |
| R&D | ||||||||||
| Change (%) | ||||||||||
| % of Revenue | ||||||||||
| OpEx | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | -0.16 | -7.43 | 2.29 | -21.56 | -26.60 | -24.51 | 0.33 | -2.67 | -2.76 | |
| % of Revenue | 56,441.15 | 9,223.81 | 6,683.96 | 6,837.05 | 6,110.50 | 8,577.37 | 9,211.47 | 9,086.67 | 9,001.56 | 32,648.92 |
| Operating Income | -1 | -1 | -1 | -1 | -1 | -0 | -0 | -0 | -0 | -0 |
| Change (%) | -1.07 | -7.81 | 2.33 | -21.70 | -26.25 | -24.45 | 0.31 | -2.68 | -1.97 | |
| % of Revenue | -56,341.15 | -9,123.81 | -6,583.96 | -6,737.05 | -6,010.50 | -8,477.37 | -9,111.47 | -8,986.67 | -8,901.56 | -32,548.92 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Change (%) | 37.44 | 25.60 | 71.42 | 32.08 | 29.78 | 25.83 | 9.06 | 13.08 | 10.05 | |
| % of Revenue | -1,088.94 | -244.98 | -240.86 | -412.88 | -621.36 | -1,542.18 | -2,760.38 | -2,959.81 | -3,406.76 | -13,984.35 |
| Net Income | -1 | -1 | -1 | -4 | -4 | -4 | -4 | -0 | -0 | -0 |
| Change (%) | 0.68 | -9.11 | 399.06 | -3.82 | -3.50 | -2.01 | -98.17 | 65.85 | -27.98 | |
| % of Revenue | -60,843.17 | -10,026.28 | -7,133.53 | -35,600.34 | -39,014.35 | -72,000.00 | -100,366.41 | -1,806.86 | -3,050.05 | -8,193.91 |
Source: Capital IQ
